Introduction Efficacy and safety of roflumilast cream, a potent phosphodiesterase 4 inhibitor, were demonstrated in phase 3 trials of mild-to-moderate atopic dermatitis (AD) in patients aged ≥2 years. This analysis evaluated caregiver-reported outcomes from the phase 2, single-arm, open-label INTEGUMENT-INFANT (NCT06998056) trial of roflumilast cream 0.05% in infants aged 3 to <24 months with AD. Methods Caregivers of infants with AD (Validated Investigator Global Assessment for AD mild/moderate [2/3]; ≥3% body surface area affected) applied roflumilast cream 0.05% once daily for 4 weeks. Caregiver-reported outcomes included Worst Scratch/Itch–Numeric Rating Scale (WSI-NRS; score range: 0–10) success (≥4-point improvement from baseline in patients with baseline WSI-NRS ≥4), Dynamic Pruritus Score–25 (DPS-25; ≥25% itch improvement from baseline in patients with baseline WSI-NRS >0), Patient-Oriented Eczema Measure (POEM; 0–28), Infant’s Dermatitis Quality of Life Index (IDQoL; 0–30), and the Dermatitis Family Impact questionnaire (DFI; 0–30). Results In total, 101 patients were enrolled. After the first application of roflumilast cream 0.05%, 10.4% (8/77) of patients achieved WSI-NRS success at 24 hours and 46.6% (41/88) achieved DPS-25 at 10 minutes. WSI-NRS success was achieved by 72.7% (56/77) of patients at their last assessment. Mean total scores improved from baseline to week 4 by 3.5 for WSI-NRS, 7.9 for POEM, 5.0 for IDQoL, and 5.1 for DFI. Conclusion Among caregiver-reported outcomes, roflumilast cream 0.05% demonstrated rapid improvement in itch and improved AD signs/symptoms, infant quality of life, and family impact through 4 weeks in patients aged 3 to <24 months with AD.
We examine linkages among important wheat trading markets during the U.S. postbellum period. These markets underwent important improvements in infrastructure over this period, including the development of an extensive rail system. We utilize hidden Markov models with endogenous dynamics to evaluate these market linkages. This approach is unique in that the transition between hidden regimes is allowed to be dependent on contemporaneous market conditions. We find that larger deviations from parity underlie a transition between regimes, with one regime characterized by greater price volatility. During periods of greater deviations from price parity, the response of markets to such deviations is greater and occurs with faster equilibrating adjustments, as is indicated by smaller half-lives for parity deviations.
In the African Sahel, an increase in temperature, heatwaves, desertification, drought, floods, loss of ecosystems, and collapse of livelihoods are forcing vulnerable populations to migrate from their habitat. These climate-related stressors interact with poverty, insecurity, armed conflict, and weak institutions, creating complex displacement dynamics. But despite the scale and intensity of climate-induced migration in the Sahel region, existing international refugee, human rights, and climate change governance systems do not provide adequate protection for climate-displaced persons. This is because climate-displaced persons are deemed “invisible” under traditional protection frameworks. This study critically assesses the gaps in legal and institutional frameworks associated with climate-induced migrants in the African Sahel. The research employed a doctrinal and analytical approach in analysing doctrines of refugee law, climate governance instruments, regional frameworks in Africa, and human rights principles. The study found that the lack of cohesion between refugee law, climate governance, and migration governance is creating substantial protection gaps for climate migrants in the Sahel. These legal frameworks are institutionally unsuitable to address the compounded displacement issues affecting the region. Therefore, this research recommends a rights-based and regionally responsive framework to strengthen legal status, institutional cooperation, and protective mechanisms for climate migrants in Africa.